Positive Data Reported for Monoclonal Antibody Treatment

June 23, 2020

Positive Data Reported for Monoclonal Antibody Treatment

Humanigen has reported positive data from the first clinical use of lenzilumab, which is a humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, in 12 COVID-19 patients. Those treated with the drug fully recovered in 5 days. Yourway has been working throughout the pandemic to transport clinical trial materials to patients that need it, despite challenges involving border closure and supply chain disruptions.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Global Clinical Supplies Group Asia Pacific Conference

March 11-13, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Media

Articles

Just-in-Time or Plan Ahead? Mastering Logistics Strategies for Complex Clinical Trials

Open chat

Hello! How can I help you?